Invivyd (IVVD) Change in Accured Expenses (2021 - 2025)
Invivyd (IVVD) posted Change in Accured Expenses of -$6.0 million for Q4 2025, up 75.77% on a QoQ basis from -$24.8 million in Q3 2025, and up 15.05% year-over-year from -$5.2 million in Q4 2024.
Invivyd (IVVD) Change in Accured Expenses (2021 - 2025) Analysis & Trends
Invivyd's Change in Accured Expenses history runs 5 years deep, the most recent figure standing at -$6.0 million for Q4 2025.
- Quarterly Change in Accured Expenses rose 15.05% year-over-year to -$6.0 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$30.8 million (down 444.66% YoY) and the FY2025 annual result came in at -$30.8 million, down 444.66% from the prior year.
- Change in Accured Expenses was -$6.0 million for Q4 2025 at Invivyd, up from -$24.8 million in the prior quarter.
- Across five years, Change in Accured Expenses topped out at $51.4 million in Q4 2021 and bottomed at -$24.8 million in Q3 2025.
- A 5-year average of $2.4 million and a median of -$61500.0 in 2022 frame the typical range for Change in Accured Expenses.
- Annual changes were most pronounced in 2022 — Change in Accured Expenses slumped 333.06% — and 2024, when it soared 265541.67%.
- Invivyd's Change in Accured Expenses stood at $51.4 million in 2021, then sank by 99.81% to $97000.0 in 2022, then soared by 19673.2% to $19.2 million in 2023, then tumbled by 136.92% to -$7.1 million in 2024, then climbed by 15.05% to -$6.0 million in 2025.
- Business Quant data shows IVVD's Change in Accured Expenses at -$6.0 million in Q4 2025, -$24.8 million in Q3 2025, and $10.0 million in Q2 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | 1.13 Mn |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | 931,000.00 |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | -16.82 Mn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 23.10 Mn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | 107.70 Mn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | -16.74 Mn |
| 10 | Invivyd | 104.07 Mn | -122.62 Mn | 16.07 Mn | -6.02 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -6.02 Mn |
| Dec 31, 2025 | -6.02 Mn |
| Sep 30, 2025 | -24.83 Mn |
| Sep 30, 2025 | -24.83 Mn |
| Jun 30, 2025 | 10.01 Mn |
| Jun 30, 2025 | 10.01 Mn |
| Mar 31, 2025 | -10.01 Mn |
| Mar 31, 2025 | -10.01 Mn |
| Dec 31, 2024 | -7.08 Mn |
| Dec 31, 2024 | -7.08 Mn |
| Sep 30, 2024 | 31.85 Mn |
| Sep 30, 2024 | 31.85 Mn |
| Jun 30, 2024 | -8.86 Mn |
| Jun 30, 2024 | -8.86 Mn |
| Mar 31, 2024 | -6.96 Mn |
| Mar 31, 2024 | -6.96 Mn |
| Dec 31, 2023 | 19.18 Mn |
| Dec 31, 2023 | 19.18 Mn |
| Sep 30, 2023 | -12,000.00 |
| Sep 30, 2023 | -12,000.00 |